主管单位:中华人民共和国
国家卫生健康委员会
主办单位:
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
英文作者:
单位:150040哈尔滨,黑龙江中医药大学附属第一医院内分泌科(仲维莉),心血管一科(邹国良)
英文单位:
英文关键词:
【摘要】目的 探讨初发与血糖控制不佳的2型糖尿病患者应用门冬胰岛素30注射液强化治疗的效果及安全性。方法 选取2016年1月至2018年6月黑龙江中医药大学附属第一医院收治的2型糖尿病住院患者126例,其中初发(病程<1年)的2型糖尿病66例(A组),病程>5年血糖控制不佳的2型糖尿病60例(B组)。2组患者均在饮食、运动干预的基础上应用门冬胰岛素30注射液皮下注射治疗3次/d。比较2组患者入院时、治疗2周出院时以及治疗3个月随访时三餐前后各时点指尖血糖的变化,住院期间血糖控制达标的每日胰岛素总量,治疗3个月随访时糖化血红蛋白(HbA1c)和降糖方案的变化,以及治疗3个月期间低血糖的发生率。结果 A组和B组治疗2周出院时以及治疗3个月随访时空腹、早餐后、午餐前、午餐后、晚餐前、晚餐后和睡前指尖血糖水平均低于入院时水平,差异均有统计学意义(均P<0.05)。A组住院期间血糖控制达标的每日胰岛素总量低于B组[(36±5)U/d比(52±12)U/d],差异有统计学意义(P<0.05)。入院时2组 HbA1c水平比较差异无统计学意义(P>0.05),A组和B组治疗3个月随访时HbA1c水平均低于入院时[(7.3±0.3)%比(9.8±0.8)%,(7.5±0.5)%比(9.8±0.6)%],差异均有统计学意义(均P<0.05)。治疗3个月随访时,A组66例患者中18例(27.3%)改为门冬胰岛素30注射液每日2次皮下注射,22例(33.3%)改为口服降糖药物治疗,26例(39.4%)仅采用饮食、运动疗法即可控制血糖;B组60例患者仍继续应用胰岛素治疗,6例(10.0%)患者改为每日2次皮下注射门冬胰岛素30注射液,16例(26.7%)患者继续维持强化治疗方案,38例(63.3%)患者改为每日2次皮下注射门冬胰岛素30注射液联合口服降糖药物治疗。治疗3个月期间2组低血糖发生率比较差异无统计学意义(P>0.05)。结论 门冬胰岛素30注射液强化治疗对初发2型糖尿病和血糖控制不佳的2型糖尿病患者均疗效较好,安全性较高。
【Abstract】Objective To analyze the efficacy and safety of insulin aspart 30 in the treatment of initial type 2 diabetes and long course type 2 diabetes with poor glycemic control. Methods Totally 126 patients with type 2 diabetes were enrolled from First Affiliated Hospital, Heilongjiang University of Chinese Medicine between January 2016 and June 2018, including 66 cases of initial diabetes(course of disease<1 year, group A) and 60 cases with poor glycemic control(course of disease>5 years, group B). All patients were treated with insulin aspart 30 subcutaneous injection 3 times per day on the basis of diet and exercise intervention. Preprandial and postprandial blood glucose levels were tested at admission, 2 weeks and 3 months after treatment. Daily insulin dose to reach the standard blood glucose level was recorded during hospitalization. Glycosylated hemoglobin(HbA1c) level, changes of hypoglycemic regimen and incidence of hypoglycemia were analyzed 3 months after treatment. Results Preprandial and postprandial blood glucose levels of 3 meals and blood glucose level at bedtime 2 weeks and 3 months after treatment were significantly lower than those at admission in both group A and group B(P<0.05). Daily insulin dose during hospitalization in group A was significantly lower than that in group B[(36±5)U/d vs (52±12)U/d](P<0.05). HbA1c level at admission was similar between groups(P>0.05). HbA1c level 3 months after treatment was significantly lower than that at admission in group A and group B[(7.3±0.3)% vs (9.8±0.8)%, (7.5±0.5)% vs (9.8±0.6)%](P<0.05). At 3 months after treatment, 18 of 66 patients in group A(27.3%) had insulin aspart 30 injection 2 times per day; 22 patients(33.3%) took hypoglycemic agents orally; 26 patients(39.4%) stopped hypoglycemic medication; all the 60 patients in group B still need insulin subcutaneous injection; 6 patients(10.0%) had insulin aspart 30 injection 2 times per day; 16 patients(26.7%) continued to have insulin aspart 30 injection 3 times per day; 38 patients(63.3%) had insulin aspart 30 injection 2 times per day plus oral hypoglycemic agents. There was no significant difference of the incidence of hypoglycemia between groups during 3 months of treatment(P>0.05). Conclusion Intensive insulin aspart 30 treatment is safe and effective in treating initial type 2 diabetes and long course type 2 diabetes with poor glycemic control.
copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。